Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists

Abstract Gonadotrophin-releasing hormone agonists (GnRHAs) are used in many clinical conditions, particularly prostate cancer. There have been a few case reports of apoplexy from a previously undiagnosed pituitary tumour, occurring within hours to days of initiation of GnRHA therapy. We report a cas...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical neuroscience 2010-09, Vol.17 (9), p.1201-1203
Main Authors: Sinnadurai, M, Cherukuri, R.K, Moses, R.G, Nasser, E
Format: Article
Language:English
Subjects:
Aged
Apoplexy
Drug Implants - administration & dosage
Drug Implants - adverse effects
GnRH
Gonadotropin-Releasing Hormone - agonists
Goserelin
Goserelin - administration & dosage
Goserelin - adverse effects
Humans
Male
Neurology
Pituitary
Pituitary Apoplexy - chemically induced
Pituitary Apoplexy - diagnosis
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Prostrate
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Gonadotrophin-releasing hormone agonists (GnRHAs) are used in many clinical conditions, particularly prostate cancer. There have been a few case reports of apoplexy from a previously undiagnosed pituitary tumour, occurring within hours to days of initiation of GnRHA therapy. We report a case of delayed onset pituitary apoplexy following GnRHA therapy. A 71-year-old man presented three weeks after onset of headache and vision loss. On examination, he was blind in the right eye with an intact nasal field of vision in the left eye. Two months before presentation, he had a subcutaneous GnRHA (Goserelin) implant for treatment of locally advanced prostate cancer (Gleeson 4+3). An MRI scan revealed a large sellar/suprasellar mass. His follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels were grossly elevated. A trans-sphenoidal endoscopic decompression of the pituitary tumour was performed. His vision improved post-operatively and his FSH, LH, testosterone, prostate specific antigen (PSA) levels returned to normal levels. Histopathologic studies revealed a pituitary adenoma, which stained positive for FSH and LH. The prostate cancer management was changed to an anti-androgen agent and a GnRH antagonist. This case demonstrates that pituitary apoplexy can develop up to eight weeks after the initiation of treatment for prostate cancer with GnRHAs.
ISSN:0967-5868
1532-2653
DOI:10.1016/j.jocn.2010.01.012